Assessment of Clinical Analgesic Levels and Serum Biomarkers in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial Comparing the Efficacy of Diclofenac and Methotrexate Combined Therapy with Extracorporeal Shockwave Therapy

Background. Rheumatoid arthritis (RA) is one of the most common forms of arthritis. Extracorporeal shockwave therapy (ESWT) has been identified as a viable alternative therapeutic approach in light of the present protracted clinical course of pharmacological treatment, and changes in levels of marke...

Full description

Saved in:
Bibliographic Details
Main Authors: Mei Zhang, Zhongyuan Ma, Rinkiko Suguro, Menglin Zhu, Esther Xinyi Chen, Xin Dong, Meixiu Chen, Linling Cheng, Bolun Su, Yizhun Zhu
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Pain Research and Management
Online Access:http://dx.doi.org/10.1155/2024/6687987
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832543652639932416
author Mei Zhang
Zhongyuan Ma
Rinkiko Suguro
Menglin Zhu
Esther Xinyi Chen
Xin Dong
Meixiu Chen
Linling Cheng
Bolun Su
Yizhun Zhu
author_facet Mei Zhang
Zhongyuan Ma
Rinkiko Suguro
Menglin Zhu
Esther Xinyi Chen
Xin Dong
Meixiu Chen
Linling Cheng
Bolun Su
Yizhun Zhu
author_sort Mei Zhang
collection DOAJ
description Background. Rheumatoid arthritis (RA) is one of the most common forms of arthritis. Extracorporeal shockwave therapy (ESWT) has been identified as a viable alternative therapeutic approach in light of the present protracted clinical course of pharmacological treatment, and changes in levels of marker proteins in the blood samples of RA patients can be utilized to assess treatment outcomes. Methods. A randomized controlled trial was conducted involving forty patients diagnosed with rheumatoid arthritis (RA) who were assigned randomly to two groups. The first group received a combination of diclofenac and methotrexate (MTX) consisting of 25 mg of diclofenac administered thrice daily and 15 mg of MTX administered once weekly. Individual follow-up assessments were carried out after 7 and 14 days. Meanwhile, patients in the second group underwent two sessions of Extracorporeal Shockwave Therapy (ESWT), with a 7-day interval between sessions. Evaluations were conducted on day 7 and day 14. Patients who displayed pain control and stability were advised to continue the treatment, whereas those who had inflammation and discomfort were administered specific medications, and their progress was closely monitored until day 28. Blood samples were collected from both groups prior to treatment, after the first treatment, and after the second treatment. Four marker proteins (NRP-1, CELF-6, COX-2, and RGS-1) and two inflammatory cytokines (IL-6 and IL-17) were measured using western blot and RT-PCR techniques. A statistical analysis was conducted on the levels of specific proteins and inflammatory factors before and after treatment to evaluate its impact. Result. Both groups exhibited statistically significant differences in the serum level of target biomarkers before and after the intervention. However, the ESWT group demonstrated a more noticeable effect, while the diclofenac + MTX group exhibited a delayed anti-inflammatory effect compared to ESWT. Conclusion. Both treatments significantly improved joint function, relieved pain, and reduced inflammation in patients. However, ESWT demonstrated a more prominent clinical analgesic effect compared to the combination treatment of diclofenac and MTX. Furthermore, ESWT produced a more immediate and noteworthy anti-inflammatory impact by regulating NRP-1 expression, a trophic factor receptor that facilitates vascular endothelial cell migration and tissue repair through angiogenesis, and regulating RGS-1 to limit inflammatory signal transmission and immune cell activation.
format Article
id doaj-art-94deb33aac244da4a15049c6f7f66247
institution Kabale University
issn 1918-1523
language English
publishDate 2024-01-01
publisher Wiley
record_format Article
series Pain Research and Management
spelling doaj-art-94deb33aac244da4a15049c6f7f662472025-02-03T11:35:31ZengWileyPain Research and Management1918-15232024-01-01202410.1155/2024/6687987Assessment of Clinical Analgesic Levels and Serum Biomarkers in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial Comparing the Efficacy of Diclofenac and Methotrexate Combined Therapy with Extracorporeal Shockwave TherapyMei Zhang0Zhongyuan Ma1Rinkiko Suguro2Menglin Zhu3Esther Xinyi Chen4Xin Dong5Meixiu Chen6Linling Cheng7Bolun Su8Yizhun Zhu9School of Pharmacy and State Key Laboratory for the Quality Research of Chinese MedicineDepartment of Cardiothoracic SurgerySchool of Pharmacy and State Key Laboratory for the Quality Research of Chinese MedicineSchool of Pharmacy and State Key Laboratory for the Quality Research of Chinese MedicineFaculty of MedicineMacau Institute of Systems EngineeringSemiahmoo Secondary SchoolFaculty of MedicineFaculty of Chinese MedicineSchool of Pharmacy and State Key Laboratory for the Quality Research of Chinese MedicineBackground. Rheumatoid arthritis (RA) is one of the most common forms of arthritis. Extracorporeal shockwave therapy (ESWT) has been identified as a viable alternative therapeutic approach in light of the present protracted clinical course of pharmacological treatment, and changes in levels of marker proteins in the blood samples of RA patients can be utilized to assess treatment outcomes. Methods. A randomized controlled trial was conducted involving forty patients diagnosed with rheumatoid arthritis (RA) who were assigned randomly to two groups. The first group received a combination of diclofenac and methotrexate (MTX) consisting of 25 mg of diclofenac administered thrice daily and 15 mg of MTX administered once weekly. Individual follow-up assessments were carried out after 7 and 14 days. Meanwhile, patients in the second group underwent two sessions of Extracorporeal Shockwave Therapy (ESWT), with a 7-day interval between sessions. Evaluations were conducted on day 7 and day 14. Patients who displayed pain control and stability were advised to continue the treatment, whereas those who had inflammation and discomfort were administered specific medications, and their progress was closely monitored until day 28. Blood samples were collected from both groups prior to treatment, after the first treatment, and after the second treatment. Four marker proteins (NRP-1, CELF-6, COX-2, and RGS-1) and two inflammatory cytokines (IL-6 and IL-17) were measured using western blot and RT-PCR techniques. A statistical analysis was conducted on the levels of specific proteins and inflammatory factors before and after treatment to evaluate its impact. Result. Both groups exhibited statistically significant differences in the serum level of target biomarkers before and after the intervention. However, the ESWT group demonstrated a more noticeable effect, while the diclofenac + MTX group exhibited a delayed anti-inflammatory effect compared to ESWT. Conclusion. Both treatments significantly improved joint function, relieved pain, and reduced inflammation in patients. However, ESWT demonstrated a more prominent clinical analgesic effect compared to the combination treatment of diclofenac and MTX. Furthermore, ESWT produced a more immediate and noteworthy anti-inflammatory impact by regulating NRP-1 expression, a trophic factor receptor that facilitates vascular endothelial cell migration and tissue repair through angiogenesis, and regulating RGS-1 to limit inflammatory signal transmission and immune cell activation.http://dx.doi.org/10.1155/2024/6687987
spellingShingle Mei Zhang
Zhongyuan Ma
Rinkiko Suguro
Menglin Zhu
Esther Xinyi Chen
Xin Dong
Meixiu Chen
Linling Cheng
Bolun Su
Yizhun Zhu
Assessment of Clinical Analgesic Levels and Serum Biomarkers in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial Comparing the Efficacy of Diclofenac and Methotrexate Combined Therapy with Extracorporeal Shockwave Therapy
Pain Research and Management
title Assessment of Clinical Analgesic Levels and Serum Biomarkers in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial Comparing the Efficacy of Diclofenac and Methotrexate Combined Therapy with Extracorporeal Shockwave Therapy
title_full Assessment of Clinical Analgesic Levels and Serum Biomarkers in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial Comparing the Efficacy of Diclofenac and Methotrexate Combined Therapy with Extracorporeal Shockwave Therapy
title_fullStr Assessment of Clinical Analgesic Levels and Serum Biomarkers in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial Comparing the Efficacy of Diclofenac and Methotrexate Combined Therapy with Extracorporeal Shockwave Therapy
title_full_unstemmed Assessment of Clinical Analgesic Levels and Serum Biomarkers in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial Comparing the Efficacy of Diclofenac and Methotrexate Combined Therapy with Extracorporeal Shockwave Therapy
title_short Assessment of Clinical Analgesic Levels and Serum Biomarkers in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial Comparing the Efficacy of Diclofenac and Methotrexate Combined Therapy with Extracorporeal Shockwave Therapy
title_sort assessment of clinical analgesic levels and serum biomarkers in patients with rheumatoid arthritis a randomized controlled trial comparing the efficacy of diclofenac and methotrexate combined therapy with extracorporeal shockwave therapy
url http://dx.doi.org/10.1155/2024/6687987
work_keys_str_mv AT meizhang assessmentofclinicalanalgesiclevelsandserumbiomarkersinpatientswithrheumatoidarthritisarandomizedcontrolledtrialcomparingtheefficacyofdiclofenacandmethotrexatecombinedtherapywithextracorporealshockwavetherapy
AT zhongyuanma assessmentofclinicalanalgesiclevelsandserumbiomarkersinpatientswithrheumatoidarthritisarandomizedcontrolledtrialcomparingtheefficacyofdiclofenacandmethotrexatecombinedtherapywithextracorporealshockwavetherapy
AT rinkikosuguro assessmentofclinicalanalgesiclevelsandserumbiomarkersinpatientswithrheumatoidarthritisarandomizedcontrolledtrialcomparingtheefficacyofdiclofenacandmethotrexatecombinedtherapywithextracorporealshockwavetherapy
AT menglinzhu assessmentofclinicalanalgesiclevelsandserumbiomarkersinpatientswithrheumatoidarthritisarandomizedcontrolledtrialcomparingtheefficacyofdiclofenacandmethotrexatecombinedtherapywithextracorporealshockwavetherapy
AT estherxinyichen assessmentofclinicalanalgesiclevelsandserumbiomarkersinpatientswithrheumatoidarthritisarandomizedcontrolledtrialcomparingtheefficacyofdiclofenacandmethotrexatecombinedtherapywithextracorporealshockwavetherapy
AT xindong assessmentofclinicalanalgesiclevelsandserumbiomarkersinpatientswithrheumatoidarthritisarandomizedcontrolledtrialcomparingtheefficacyofdiclofenacandmethotrexatecombinedtherapywithextracorporealshockwavetherapy
AT meixiuchen assessmentofclinicalanalgesiclevelsandserumbiomarkersinpatientswithrheumatoidarthritisarandomizedcontrolledtrialcomparingtheefficacyofdiclofenacandmethotrexatecombinedtherapywithextracorporealshockwavetherapy
AT linlingcheng assessmentofclinicalanalgesiclevelsandserumbiomarkersinpatientswithrheumatoidarthritisarandomizedcontrolledtrialcomparingtheefficacyofdiclofenacandmethotrexatecombinedtherapywithextracorporealshockwavetherapy
AT bolunsu assessmentofclinicalanalgesiclevelsandserumbiomarkersinpatientswithrheumatoidarthritisarandomizedcontrolledtrialcomparingtheefficacyofdiclofenacandmethotrexatecombinedtherapywithextracorporealshockwavetherapy
AT yizhunzhu assessmentofclinicalanalgesiclevelsandserumbiomarkersinpatientswithrheumatoidarthritisarandomizedcontrolledtrialcomparingtheefficacyofdiclofenacandmethotrexatecombinedtherapywithextracorporealshockwavetherapy